|Bid||7.67 x 1100|
|Ask||7.75 x 800|
|Day's Range||7.45 - 7.79|
|52 Week Range||5.26 - 14.00|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 06, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.75|
PHILADELPHIA, May 27, 2020 -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of shareholders Pfenex Inc. (“Pfenex” or the “Company”) (NYSE: PFNX).
NEW YORK, May 27, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Pfenex Inc. (“Pfenex” or the “Company”) (NYSE: PFNX). Such investors are advised to.
The latest analyst coverage could presage a bad day for Pfenex Inc. (NYSEMKT:PFNX), with the analysts making...
Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform, Pfenex Expression Technology®, to develop next generation and novel protein therapeutics to meaningfully improve existing therapies and create novel therapies for some of the biological targets linked to critical diseases still waiting to successfully be addressed. Pfenex has developed a pipeline that is diversified across multiple assets, including a U.S. Food and Drug Administration (FDA)-approved PF708 product indicated for the treatment of osteoporosis in certain patients at high risk for fracture, and novel and next generation therapeutic product candidates. “We believe this is an exciting time for Pfenex as we continue to work toward opportunities and potential milestones for our three lead programs: PF708, including the FDA-approved PF708 product, our collaboration with Jazz Pharmaceuticals to develop PF743 (JZP-458) and PF745 (JZP-341), as well as our CRM197 based collaborations,” stated Eef Schimmelpennink, Chief Executive Officer of Pfenex.
SAN DIEGO, April 24, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pfenex Inc. ("Pfenex" or "the Company") (NASDAQ: PFNX). Investors who purchased Pfenex securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/pfnx.
Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA), informed Alvogen Malta Operations Ltd., the Company’s commercialization partner for PF708, via a General Advice letter that additional comparative use human factors (CUHF) data, specifically from Forteo® (teriparatide injection) experienced users, would be required before PF708 Therapeutic Equivalence (TE) could be determined. “While the previously submitted CUHF study included Forteo-experienced patients and caregivers, the FDA requested that a larger number of experienced subjects be studied,” stated Eef Schimmelpennink, Chief Executive Officer of Pfenex.
Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has developed the FDA-approved PF708 product indicated for the treatment of osteoporosis in certain patients at high risk for fracture and created an advanced pipeline of therapeutic equivalents, biologics and vaccines in various stages of development. Today Pfenex Inc. reported financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.
NEW YORK, NY / ACCESSWIRE / March 11, 2020 / Pfenex Inc (NYSEAMERICAN:PFNX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, 2020 at 4:30 PM ...
SAN DIEGO, Feb. 26, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019,.
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO) prequalification for Pneumosil, a 10-valent pneumococcal conjugate vaccine. Pneumosil contains the recombinant carrier protein CRM197 produced by Serum Institute under a license to the Pfenex Expression Technology®. Under the agreement with Serum Institute, Pfenex is eligible to receive annual fees, milestone payments, and a tiered low single digit royalty based on net sales for all products developed by Serum Institute that use the CRM197 carrier protein produced via the Pfenex Expression Technology.
Is Pfenex Inc (NYSE:PFNX) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated with process development activities for PF745, a long-acting Erwinia asparaginase. “We are very pleased with the rapid progression of the PF745 program and we believe the Jazz collaboration, overall, further validates the versatility of our proprietary protein expression platform and the quality of our development capabilities,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. Under the terms of the development and license agreement, Pfenex is eligible to receive an aggregate total of up to $224.5 million in development and sales milestones, of which $162.5 million is still eligible to be received by Pfenex, including up to $3.5 million for development milestones, $34 million in regulatory milestones and $125 million in sales milestones.
SAN DIEGO, Nov. 20, 2019 -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to.
SAN DIEGO, Nov. 19, 2019 -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to.
Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial Officer effective November 13, 2019, but will continue to support the company by providing transition services until February 1, 2020. Pfenex's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Pfenex (PFNX) delivered earnings and revenue surprises of 0.00% and 3.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA.
SAN DIEGO, Nov. 06, 2019 -- Pfenex Inc. (NYSE American: PFNX) today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the.